1. Home
  2. CRMD

as 09-12-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Founded: 2006 Country:
United States
United States
Employees: N/A City: BERKELEY HEIGHTS
Market Cap: 925.6M IPO Year: 2010
Target Price: $17.57 AVG Volume (30 days): 4.6M
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.79 EPS Growth: N/A
52 Week Low/High: $5.60 - $17.43 Next Earning Date: 10-29-2025
Revenue: $121,484,498 Revenue Growth: 14970.29%
Revenue Growth (this year): 404.81% Revenue Growth (next year): 56.11%

CRMD Daily Stock ML Predictions

Stock Insider Trading Activity of CorMedix Inc. (CRMD)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Masson-Hurlburt Elizabeth CRMD Chief Operating Officer Sep 11 '25 Sell $13.08 41,121 $537,862.68 176,990
Zelnick Kaufman Beth CRMD Chief Legal Officer Sep 9 '25 Sell $13.12 50,000 $670,264.00 180,818
Masson-Hurlburt Elizabeth CRMD Chief Operating Officer Sep 9 '25 Sell $13.51 12,876 $173,954.76 176,990

Share on Social Networks: